Background/Aims: Hyperprolactinaemia is a common cause of amenorrhoea due to hypogonadotropic hypogonadism. Prolactin is hypothesised to impede the reproductive axis through an inhibitory action at the hypothalamus. However, limited data exist to aid the interpretation of serum gonadotropins in the context of hyperprolactinaemia. Methods: Serum gonadotropin values were reviewed in 243 patients with elevated serum monomeric prolactin due to discrete aetiologies at a tertiary reproductive endocrine centre between 2012 and 2015. The cause of hyperprolactinaemia was categorised by an experienced endocrinologist/pituitary multidisciplinary team, unless superseded by histology. The most frequently encountered diagnoses were microprolactinoma (n = 88), macroprolactinoma (n = 46), non-functioning pituitary adenoma (NFPA) (n = 72), drug-induced hyperprolactinaemia (n = 22) and polycystic ovarian syndrome (PCOS) (n = 15). Results: In patients with prolactinoma and modestly raised serum prolactin levels (< 4,000 mU/L), increasingly FSH-predominant gonadotropin values were observed with rising prolactin level, consistent with a progressive reduction in hypothalamic gonadotropin-releasing hormone (GnRH) pulsatility. Patients with prolactinoma and higher prolactin values (> 4,000 mU/L) were more likely to have a reduction in serum levels of both FSH and LH, consistent with direct pituitary gonadotrope dysfunction. Patients with macroadenoma and extremes of serum gonadotropin values (either serum FSH or LH > 8 IU/L) were more likely to have NFPA than prolactinoma. Patients with PCOS and hyperprolactinaemia had LH-predominant secretion in keeping with increased GnRH pulsatility despite a raised prolactin level. Conclusion: The pattern of gonadotropin secretion in patients with hyperprolactinaemia reflects the underlying aetiology.
Introduction
Hyperprolactinaemia is diagnosed five-fold more frequently in women than men and is one of the most frequent causes of secondary amenorrhoea [1, 2] . Hyperprolactinaemia may result from a number of different aetiologies: prolactinoma autonomously secreting pro-DOI: 10 .1159/000489264 lactin from the pituitary gland (∼50% of cases), disconnection hyperprolactinaemia due to a "non-functioning pituitary adenoma" (NFPA) removing tonic dopamine inhibition of prolactin secretion (∼7% of cases), drug-induced hyperprolactinaemia (DIH) reducing inhibitory dopamine action (∼15% of cases) [3] and polycystic ovarian syndrome (PCOS) [4] . However, the mechanism by which hyperprolactinaemia results in hypogonadotropic hypogonadism remains the subject of conjecture, and sparse data currently exist to aid the endocrinologist in the interpretation of serum gonadotropin levels in the context of hyperprolactinaemia.
Prolactin is believed to mediate its inhibitory effect on the reproductive axis by reducing secretion of gonadotropin-releasing hormone (GnRH) neurons from the hypothalamus [2] . Consistent with this, LH pulse amplitude and frequency are reduced in rodents and humans rendered hyperprolactinaemic [5] [6] [7] , due to decreased portal GnRH levels [8] [9] [10] . Moreover, pulsatile GnRH administration stimulates LH secretion in patients with hyperprolactinaemia [10] sufficient to restore fertility [11] , suggesting that pituitary gland function is unperturbed during hyperprolactinaemia. However, the majority of GnRH neurons do not possess the prolactin receptor [12] , and thus prolactin is not believed to directly inhibit GnRH neurons. In summary, prolactin is believed to cause hypogonadotropic hypogonadism by reducing hypothalamic function, likely through an intermediary neuron.
Recently, hypothalamic kisspeptin neurons have been proposed as putative mediators of the inhibitory effect of prolactin on the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin neurons are key regulators of the HPG axis controlling hypothalamic GnRH secretion [13] [14] [15] . The majority of kisspeptin neurons express the prolactin receptor [2, 16] ; and hypothalamic kisspeptin immunoreactivity is reduced in a hyperprolactinaemic rodent model [16] . Furthermore, exogenous kisspeptin administration stimulates pulsatile gonadotropin secretion in both hyperprolactinaemic humans and rodents [16] [17] [18] . Thus, prolactin is hypothesised to act at the hypothalamus to reduce GnRH secretion and result in hypogonadotropic hypogonadism (Fig. 1a) .
A curious property of pituitary gonadotropes is that the secretion of gonadotropins (LH and FSH) is modulated by the frequency of hypothalamic GnRH secretion [19] . For example, GnRH pulse frequency is increased in PCOS, and thus LH-predominant secretion is favoured [19] . By contrast, causes of reduced GnRH pulsatility such as hypothalamic amenorrhoea (and as suggested by the current literature also hyperprolactinaemia) favour FSH-predominant secretion [19] .
Thus, we hypothesised that causes of hyperprolactinaemia in which pituitary gonadotropes are structurally unperturbed (e.g., DIH or microprolactinoma) would result in FSH-predominant gonadotropin secretion due to a reduction in hypothalamic GnRH pulsatility (Fig. 1a) . However, causes of hyperprolactinaemia that could result in direct disruption of pituitary gonadotrope function, such as pituitary macroadenomas causing hypopituitarism, would lead to a reduction in both serum FSH and LH levels (Fig. 1b) .
To investigate this, we conducted a review of serum gonadotropin values in 243 patients presenting with hyperprolactinaemia to investigate whether discrete patterns of gonadotropin secretion could be ascertained in hyperprolactinaemia of distinct aetiologies.
Methods

Study Design
We undertook a retrospective analysis of serum gonadotropin values in patients attending Imperial College NHS Healthcare Trust, UK, between January 2012 and December 2015 with elevated serum monomeric prolactin levels.
Study Participants
Inclusion criteria included the presence of elevated serum monomeric prolactin above the gender-specific reference range with simultaneous measurement of serum gonadotropin levels. Imperial College Healthcare NHS Trust offers a specialist endocrine and pituitary service and accepts referrals from primary care practitioners across London. All patients referred for investigation of a pituitary adenoma, or with relevant symptoms such as menstrual disturbance or galactorrhoea in females/hypogonadal symptoms in males, will have a further serum prolactin assessment in secondary care. All patients with a serum prolactin above the gender-specific reference range are routinely screened for the presence of macroprolactin by PEG precipitation in our laboratory. In this series, all patients with macroprolactin identified had only mild elevations of serum prolactin such that serum prolactin levels were within the reference range after correction for the presence of macroprolactin. Thus, all patients with macroprolactin were subsequently excluded from further analysis. An MRI pituitary scan is conducted in all patients with a persistently raised serum prolactin to > 1,000 mU/L, and at milder serum prolactin elevations if indicated due to concern regarding possibility of pituitary adenoma. Patients who were pregnant, lactating or had evidence of concomitant renal impairment at the time of serum hyperprolactinaemia were excluded from analysis. Participants noted to be postmenopausal (n = 37), or periovulatory despite hyperprolactinaemia (n = 3) were also excluded to avoid distortion of serum gonadotropin levels due to negative or positive feedback from sex steroid levels. Cause of Hyperprolactinaemia Clinical assessment including medical history, drug history and physical examination were performed by the attending physician at the time of referral to Imperial College NHS Healthcare Trust, UK. The aetiology of hyperprolactinaemia was determined by the attending physician/pituitary multidisciplinary team incorporating clinical details and response to treatment, unless superseded by histological confirmation if surgical treatment was carried out. All patients included in analysis of pretreatment presenting serum prolactin level and tumour size diagnosed with NFPA had histological confirmation, but this was not available for patients diagnosed with prolactinoma as medical management is preferred. However, patients with serum prolactin more than 2,000 mU/L are highly likely to have prolactinoma [20] . Patients with more than one possible aetiology of their hyperprolactinaemia, e.g. microadenoma and PCOS, were excluded from analysis. Two of 15 patients with PCOS had mild prolactin elevations which spontaneously resolved with conservative management and thus did not undergo pituitary MRI imaging. Contemporaneous measurements of serum prolactin and serum gonadotropin levels, renal function and imaging were reviewed.
Hormonal Assay Methodology
Serum LH, FSH, oestradiol and testosterone were measured using automated chemiluminescent immunoassays (Abbott Diagnostics, Maidenhead, UK). Serum prolactin was measured using Architect chemiluminescent microparticle immunoassay (Abbott Diagnostics). Interassay coefficients of variation were as follows: LH, 3.4%; FSH, 3.5%; oestradiol, 3.4%; testosterone 3.6%. Limits of detectability for each assay were as follows: LH 0.07 mIU/mL; FSH 0.05 mIU/mL; oestradiol 70 pmol/L (19 pg/mL); testosterone 0.08 nmol/L. The interassay coefficient of variation for prolactin was 4.4%. The upper limit of the reference range for men was 300 mU/L and for women was 500 mU/L. The conversion factor for prolactin from standard unit (mU/L) to ng/mL is 21. 
Statistical Analysis
Parametrically distributed variables were compared using oneway ANOVA with Dunnet's post hoc analysis, or unpaired Student's t test as appropriate. Non-parametrically distributed variables were compared using the Kruskal-Wallis test, or MannWhitney U as appropriate. Categorical data were compared by the χ 2 test, or logistic regression. p value < 0.05 was regarded as statistically significant.
Results
Baseline Characteristics
Patient records of 475 patients presenting with raised serum monomeric hyperprolactinaemia were identified, of whom 310 had contemporaneous measurement of both serum prolactin and gonadotropins (Fig. 2 ). Of these, 97 (31.1%) were male and 213 (68.7%) were female, with a median age of 42.5 years. The median prolactin level was 1,111 mU/L (IQR 684-2,262 mU/L) in our study cohort (see Table 1 for baseline characteristics).
Frequency of Menstrual Disturbance in Women with Prolactinoma
Menstrual disturbance (documented oligomenorrhoea or amenorrhoea) was reported in two-thirds of female patients with prolactinoma. In women with prolactinoma, the frequency of menstrual disturbance increased with rising serum prolactin level, from 47% of those with a serum prolactin < 1,000 mU/L, to 79.2% of women with a serum prolactin > 2,500 mU/L (Fig. 3a) . Menstrual disturbance was more frequent if serum LH was low; 90.5% of women with a serum LH ≤1.5 IU/L had menstrual disturbance as compared with 58.6% of women with higher LH values.
Serum Gonadotropin Values in Different Aetiologies of Hyperprolactinaemia
Hyperprolactinaemia due to DIH, and prolactinoma was associated with FSH-predominant gonadotropin secretion (Table 1) . Patients with macroprolactinoma (FSH 2.9 IU/L; LH 1.6 IU/L) had lower mean levels of both serum FSH and LH when compared with microprolactinoma (FSH 4.1 IU/L; LH 2.7 IU/L, p = 0.007). However, patients with PCOS and hyperprolactinaemia had LHpredominant gonadotropin values (FSH 4.2 IU/L; LH 5.1 IU/L) ( Table 1) .
Increasingly FSH-Predominant Gonadotropin Values with Rising Prolactin Level in Patients with Prolactinoma
In patients with prolactinoma, serum gonadotropin values trended towards being progressively FSH-predominant with increasing serum prolactin level up to 4,000 mU/L (Fig. 3b ). Beyond a serum prolactin level of 4,000 mU/L, both FSH and LH values were reduced (Fig. 3c, d ). This pattern of gonadotropin secretion was also observed when examining serum gonadotropin values in prolactinoma separately by gender (online suppl. Fig. 2 and 3 ; see ww.karger.com/doi/10.1159/000489264 for all online suppl. material). Whilst only 25% of patients with prolactinoma and a serum prolactin level < 4,000 mU/L had macroprolactinoma, 72% of patients with a prolactin > 4,000 mU/L had macroprolactinoma. Pre-treatment presenting serum prolactin level increased in an exponential manner with prolactinoma lesion maximal diameter (r 2 0.79; online suppl. Fig. 4) .
Patients with higher values of serum prolactin were more likely to also have deficiency of other pituitary axes (online suppl. Fig. 1A ). There was a progressive reduction in both serum FSH and LH values with increasing loss of other pituitary axes (online suppl. Fig. 1B, C) .
Serum Gonadotropin Secretion in NFPA and Macroprolactinoma
Patients with NFPA causing disconnection hyperprolactinaemia had more FSH-predominant gonadotropin values when compared with macroprolactinoma (mean FSH-LH NFPA: +2.8 IU/L, macroprolactinoma: +1.1 IU/L, p = 0.03) (Fig. 4a, b) . Patients with extremes of serum gonadotropin values (either serum FSH or LH) of > 8.0 IU/L were more likely to have NFPA than macroprolactinoma (Fig. 4c, d) . Indeed, in this dataset all patients with the sum of serum FSH and LH levels exceeding 15 IU/L had NFPA rather than macroprolactinoma (Fig. 4e) .
Discussion
Hyperprolactinaemia is one of the most frequent disorders of the HPG axis presenting to reproductive endocrinology centres [21] ; however, limited data exist on the interpretation of serum gonadotropins in the context of hyperprolactinaemia [22] [23] [24] . Insight into the pattern of gonadotropin secretion in different aetiologies of hyperprolactinaemia can aid the endocrinologist in assessing these patients.
We discern that in patients with prolactinoma, a trend towards increasingly FSH-predominant gonadotropin values is observed with rising serum prolactin level, reflective of a progressive reduction in GnRH pulsatility [25] (Fig. 1a) . This is in keeping with previous data demonstrating that normalisation of serum prolactin level by dopamine agonist treatment resulted in restoration of pulsatile LH secretion [26] . Patients with a serum prolactin over 4,000 mU/L had lower serum levels of both FSH and LH, and were more likely to have deficiencies in other pituitary axes (Fig. 1b) . Thus, reduction in gonadotropin secretion in patients with higher serum prolactin levels is likely to Mean ± SD for continuous variables and frequency (%) for categorical variables are presented for gender, age, frequency of menstrual disturbance (oligo or amenorrhoea) in women, mean serum prolactin, serum LH, serum FSH, serum FSH-LH differential and serum FSH:LH ratio for patients with prolactinoma (microadenoma; n = 88), prolactinoma (macroadenoma; n = 46), non-functioning pituitary adenoma (NFPA) (mesoadenoma; n = 13), NFPA (macroadenoma; n = 59), drug-induced hyperprolactinaemia (DIH) due to non-oral contraceptive pill (OCP) medications, e.g. neuroleptic medications (n = 16), DIH due to OCP (n = 6), and polycystic ovarian syndrome (PCOS; n = 15). Fig. 3 . Serum gonadotropin values with rising prolactin level in prolactinoma. The total number of values used is presented above each column. a The proportion of women with prolactinoma with menstrual disturbance (oligo-or amenorrhoea) by categories of serum prolactin level (n = 90; data on menstrual disturbance were missing in 4 women). The odds of menstrual disturbance increases by 47% (95% CI 4-107%; p = 0.022) for each increase in prolactin category by unadjusted logistic regression. b Mean serum FSH-LH differential (±SEM) is presented in both men and women with prolactinoma demonstrating a trend towards increasingly FSHpredominant gonadotropin values with increasing serum prolactin level up to 4,000 mU/L. The number of men (n = 40) and women (n = 94) in each serum prolactin category is as follows: < 500 M5/ F0, 500-1,000 M6/F19, 1,000-1,500 M2/F23, 1,500-2,000 M2/F14, 2,000-4,000 M7/F26, 4,000-10,000 M6/F8, > 10,000 M12/F4. These data are presented again by gender in online supplementary Dunn's multiple comparisons correction found that the following groups were significantly different from each other (500-1,000 vs. > 10,000, p = 0.014; 1,000-1,500 vs. > 10,000, p = 0.049; 1,500-2,000 vs. > 10,000, p = 0.02). d Comparison by the Kruskal-Wallis with post hoc Dunn's multiple comparisons correction found that the following groups were significantly different from each other (500-1,000 vs. > 10,000, p = 0.013; 1,000-1,500 vs. > 10,000, p = 0.048; 1,500-2,000 vs. > 10,000, p = 0.007; 2,000-4,000 vs. > 10,000, p = 0.0075). represent direct disruption of pituitary gonadotrope function (Fig. 1b) . Consistent with this interpretation, the size of a prolactinoma correlates with serum prolactin level [3, 27] (online suppl. Fig. 4 ) and prolactinomas with a serum prolactin > 3,500 mU/L are more likely to be larger lesions with invasive properties that could lead to direct pituitary gonadotrope cell dysfunction [28, 29] . Interestingly, some patients with NFPA had extremes of serum gonadotropin values (either FSH or LH) (Fig. 1c) . Whilst nominally "non-functioning," some NFPAs are in fact functional gonadotrope adenomas that directly secrete FSH or LH [30] . Patients with extremes of gonadotropin secretion (serum LH or FSH > 8 IU/L) were more likely to have NFPA causing disconnection hyperprolactinaemia than macroprolactinoma (Fig. 4c-e) . FSH-predominant secretion is more frequently observed in NFPA than LH-predominant secretion; thus, it is feasible that patients with NFPA tumours and raised LH levels had non-secretory tumours with incidental LH secretion. However, only 15 of 72 (21%) NFPAs had extremes of gonadotropin secretion > 8 IU/L and thus, initial pretreatment serum prolactin level is likely to retain greater utility in differentiating prolactinoma from NFPA [20] .
PCOS has traditionally been associated with elevated serum prolactin levels [31, 32] . Whilst some have reported that the mechanism of hyperprolactinaemia in PCOS could be due to central dysregulation of dopamine [31, 32] or elevated oestradiol levels, others have queried whether an association between PCOS and hyperprolactinaemia exists at all [33] . In our dataset, serum prolactin level was mildly elevated in patients with PCOS (serum prolactin range 656-1,982 mU/L). It is interesting to note that patients with PCOS and hyperprolactinaemia still had LH-predominant gonadotropin secretion in keeping with increased GnRH pulsatility despite a raised prolactin level [25, 34] . This could reflect the level of prolactin encountered in PCOS being too low to significantly reduce GnRH pulsatility to become FSH-predominant, or alternatively that the aetiological agent increasing GnRH pulsatility in PCOS may act downstream of prolactin's inhibitory action on the hypothalamus (Fig. 1d) . There is increasing evidence that in PCOS, anti-Mullerian hormone (AMH) could have a direct stimulatory action on GnRH neurons to increase GnRH pulsatility [35] . As such, the stimulatory action of AMH to increase GnRH pulsatility would be downstream of the inhibitory action of prolactin, and thus AMH would have a dominant effect on GnRH pulsatility (Fig. 1d) .
Patients with DIH due to medications (e.g., neuroleptic medications) that block the action of dopamine had FSHpredominant gonadotropin values in keeping with reduced GnRH pulsatility. By contrast, patients with DIH in association with oral contraceptive pill use had undetectable serum LH and FSH values in keeping with reduced pituitary gonadotrope function. This is consistent with the negative feedback of high-dose oestrogen also acting at the pituitary gland in addition to the hypothalamus (Table 1) .
In our cohort, female preponderance was observed (Table 1 ) and as in other similar studies, female patients were younger than their male counterparts (median female age 39.3 years; male age 51.4 years) [36] . Although the frequency of menstrual disturbance increased with higher serum prolactin levels in prolactinoma, interestingly some women with significantly raised prolactin levels still did not report menstrual disturbance. It is possible that frequency of menstrual disturbance in women with a prolactin level < 1,000 mU/L could have been overestimated, as some women may have reduced serum prolactin values due to panhypopituitarism, or have incidental mild elevations of serum prolactin with menstrual disturbance due to other aetiologies.
Limitations of this study include its retrospective design and that only a single prolactin level with concomitant serum gonadotropin values was evaluated. Histological confirmation of the aetiology of hyperprolactinaemia was not available for all patients, particularly in patients with prolactinomas, whereby surgical management is less often employed. Thus, there is potential for misclassification of prolactinomas with serum prolactin < 2,000 mU/L [20] . In order to avoid distortion of serum gonadotropin levels due to negative or positive feedback from sex steroid levels, we excluded postmenopausal or periovulatory patients from the analysis of change of serum gonadotropins with serum prolactin level in prolactinoma. Future larger longitudinal research studies are indicated to evaluate serum gonadotropin levels, both prior to the start of medications that could induce hyperprolactinaemia (as in the case of DIH), and following institution of dopamine agonist medications to lower serum prolactin in prolactinoma, to further inform the interpretation of serum gonadotropin levels in hyperprolactinaemia.
In summary, our data suggest that a raised serum prolactin level is associated with FSH-predominant gonadotropin secretion (e.g., FSH 4 IU/L, LH 2 IU/L) via an inhibitory action at the hypothalamus to reduce GnRH pulsatility. Undetectable gonadotropin secretion (e.g., LH 0.1 IU/L, FSH 0.1 IU/L) is more consistent with pituitary gonadotrope hypofunction and more frequently occurs in larger prolactinomas with evidence of hypopituitarism. A proportion of NFPAs are in fact functional gonadotrope adenomas directly secreting gonadotropins at levels beyond those explained by alterations in GnRH pulsatility leading to extremes of serum gonadotropin values (e.g., either FSH or LH > 8 IU/L). Patients with PCOS and a raised serum prolactin level had LH-predominant secretion (e.g., FSH 4 IU/L, LH 7 IU/L) in keeping with increased GnRH pulsatility despite a raised prolactin level. These data inform interpretation of the pattern of gonadotropin secretion in discrete aetiologies of hyperprolactinaemia and may aid the endocrinologist in the assessment of these patients as an adjunct to clinical details such as adenoma size, prolactin level and the presence of pituitary dysfunction.
